{"id":"https://openalex.org/W3135537396","doi":"https://doi.org/10.1038/s41408-021-00438-y","title":"Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma","display_name":"Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma","publication_year":2021,"publication_date":"2021-03-12","ids":{"openalex":"https://openalex.org/W3135537396","doi":"https://doi.org/10.1038/s41408-021-00438-y","mag":"3135537396","pmid":"https://pubmed.ncbi.nlm.nih.gov/33712562","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7954817"},"language":"en","primary_location":{"id":"doi:10.1038/s41408-021-00438-y","doi":"https://doi.org/10.1038/s41408-021-00438-y","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-021-00438-y","pdf_url":"https://www.nature.com/articles/s41408-021-00438-y.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.nature.com/articles/s41408-021-00438-y.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Paul_Richardson@dfci.harvard.edu","Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-7426-8865","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Paul_Richardson@dfci.harvard.edu","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024315315","display_name":"Thierry T.F. Facon","orcid":"https://orcid.org/0000-0001-7705-8460","observed_orcids":["https://orcid.org/0000-0001-7705-8460"]},"institutions":[{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Thierry Facon","raw_affiliation_strings":["Department of Haematology, Lille University Hospital, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, Lille University Hospital, Lille, France","institution_ids":["https://openalex.org/I3018718406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113514827","display_name":"William Bensinger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William I. Bensinger","raw_affiliation_strings":["Myeloma & Transplant Program, Swedish Cancer Institute, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma & Transplant Program, Swedish Cancer Institute, Seattle, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048560248","display_name":"Xavier P Leleu","orcid":"https://orcid.org/0000-0002-9822-4170","observed_orcids":["https://orcid.org/0000-0002-9822-4170"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xavier Leleu","raw_affiliation_strings":["Service d'H\u00e9matologie et Th\u00e9rapie Cellulaire, H\u00f4pital de La Mil\u00e9trie, Poitiers Cedex, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'H\u00e9matologie et Th\u00e9rapie Cellulaire, H\u00f4pital de La Mil\u00e9trie, Poitiers Cedex, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110647454","display_name":"Frank Campana","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank Campana","raw_affiliation_strings":["Sanofi-Genzyme, Cambridge, MA, USA","Takeda Pharmaceuticals, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi-Genzyme, Cambridge, MA, USA","institution_ids":[]},{"raw_affiliation_string":"Takeda Pharmaceuticals, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080347550","display_name":"Sandrine Mac\u00e9","orcid":"https://orcid.org/0000-0001-9263-6994","observed_orcids":["https://orcid.org/0000-0001-9263-6994"]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sandrine Mac\u00e9","raw_affiliation_strings":["Sanofi R&D, Vitry-sur-Seine, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi R&D, Vitry-sur-Seine, France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012837184","display_name":"Marielle Chiron","orcid":"https://orcid.org/0000-0003-0798-7066","observed_orcids":["https://orcid.org/0000-0003-0798-7066"]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marielle Chiron","raw_affiliation_strings":["Sanofi R&D, Vitry-sur-Seine, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi R&D, Vitry-sur-Seine, France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049970120","display_name":"Helgi J. Van de Velde","orcid":"https://orcid.org/0009-0004-4126-8289","observed_orcids":["https://orcid.org/0009-0004-4126-8289"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helgi van de Velde","raw_affiliation_strings":["Sanofi-Genzyme, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi-Genzyme, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058598134","display_name":"Joseph R Mikhael","orcid":"https://orcid.org/0000-0001-9670-2864","observed_orcids":["https://orcid.org/0000-0001-9670-2864"]},"institutions":[{"id":"https://openalex.org/I1284308235","display_name":"Translational Genomics Research Institute","ror":"https://ror.org/02hfpnk21","country_code":"US","type":"facility","lineage":["https://openalex.org/I1284308235"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Mikhael","raw_affiliation_strings":["Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ, USA","institution_ids":["https://openalex.org/I1284308235","https://openalex.org/I4210110459"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5043526996"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"],"apc_list":{"value":4480,"currency":"USD","value_usd":4480},"apc_paid":{"value":4480,"currency":"USD","value_usd":4480},"fwci":0.812,"has_fulltext":true,"cited_by_count":7,"citation_normalized_percentile":{"value":0.70002007,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"11","issue":"3","first_page":"55","last_page":"55"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9449999928474426},{"id":"https://openalex.org/keywords/isatuximab","display_name":"isatuximab","score":0.8529999852180481},{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/cd38","display_name":"CD38","score":0.796999990940094},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9800000190734863},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.7889999747276306},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.906000018119812}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.9711493849754333},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.720524787902832},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.6341072916984558},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5606814026832581},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5562282204627991},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5261563658714294},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.42149579524993896},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.4206400513648987},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.41692113876342773},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.09474343061447144},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1038/s41408-021-00438-y","doi":"https://doi.org/10.1038/s41408-021-00438-y","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-021-00438-y","pdf_url":"https://www.nature.com/articles/s41408-021-00438-y.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7954817","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7954817","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer J","raw_type":"Text"},{"id":"pmid:33712562","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33712562","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood cancer journal","raw_type":"Clinical Trial"},{"id":"pmh:oai:doaj.org/article:31f3b839f54a49c8a076edc5d8cd9bc3","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/31f3b839f54a49c8a076edc5d8cd9bc3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1038/s41408-021-00438-y","doi":"https://doi.org/10.1038/s41408-021-00438-y","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-021-00438-y","pdf_url":"https://www.nature.com/articles/s41408-021-00438-y.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3135537396.pdf","grobid_xml":"https://content.openalex.org/works/W3135537396.grobid-xml"},"referenced_works_count":11,"referenced_works":["https://openalex.org/W2072259475","https://openalex.org/W2425909334","https://openalex.org/W2439803058","https://openalex.org/W2592248309","https://openalex.org/W2767256995","https://openalex.org/W2776818949","https://openalex.org/W2897992036","https://openalex.org/W2922140008","https://openalex.org/W2967452512","https://openalex.org/W2988984460","https://openalex.org/W2990147138"],"related_works":["https://openalex.org/W2988522122","https://openalex.org/W4292451915","https://openalex.org/W2767256995","https://openalex.org/W3112000154","https://openalex.org/W2990147138","https://openalex.org/W4286513796","https://openalex.org/W4409069908","https://openalex.org/W4389246894","https://openalex.org/W4223493498","https://openalex.org/W2914566915"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1,106],"(MM)":[2],"is":[3,14,21,117],"the":[4,99,118],"second":[5],"most":[6],"common":[7],"hematologic":[8],"disease":[9],"worldwide":[10],"1":[11],".":[12,39,83,132],"CD38":[13,40,67,110,128],"a":[15,31,35],"type":[16],"II":[17],"transmembrane":[18],"glycoprotein":[19],"that":[20],"highly":[22],"expressed":[23],"on":[24,114],"MM":[25,115],"cells,":[26],"and":[27,33,52,79,97],"functions":[28],"both":[29,77],"as":[30,34],"receptor":[32,111],"multifunctional":[36],"ectoenzyme":[37],"2":[38],"monoclonal":[41],"antibodies":[42],"(mAbs)":[43],"exhibit":[44],"anti-MM":[45],"activity":[46],"via":[47],"multiple":[48,105],"mechanisms":[49],"of":[50,59,86,101],"action":[51],"are":[53],"being":[54],"evaluated":[55],"in":[56,71],"all":[57,63],"stages":[58],"therapy.":[60],"However,":[61],"not":[62],"patients":[64,102],"respond":[65],"to":[66,95,127],"mAb":[68],"therapy;":[69],"variability":[70],"response":[72,92,126],"may":[73],"be":[74],"explained":[75],"by":[76],"host-related":[78],"tumor-related":[80],"factors":[81],"3":[82],"The":[84],"identification":[85],"biomarkers":[87],"with":[88,103,121,124],"predictive":[89],"value":[90],"for":[91],"could":[93],"help":[94],"optimize":[96],"personalize":[98],"treatment":[100],"relapsed/refractory":[104],"(RRMM).":[107],"At":[108],"present,":[109],"density":[112],"(RD)":[113],"cells":[116],"only":[119],"biomarker":[120],"an":[122],"association":[123],"clinical":[125],"antibody":[129],"therapies":[130],"4":[131]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-03-15T00:00:00"}